{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:16:48Z","timestamp":1782847008273,"version":"3.54.5"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Innovative Science School at I. M. Sechenov First Moscow State Medical University (Sechenov University)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The diagnosis of heart failure with preserved ejection fraction (HFpEF) remains challenging. The use of metabolomics approaches seems promising in speeding up and simplifying the diagnostic process in HFpEF patients, which can lead to earlier treatment initiation and better improvement of patient condition. The aim of this study was to develop a diagnostic panel of metabolites (metabolomic biomarkers) for the detection and diagnosis of HF with preserved ejection fraction. The study included 76 participants with hypertension, 36 of whom were diagnosed with HFpEF. The blood plasma metabolomic profile, including 72 metabolites, was detected using high-performance liquid chromatography combined with mass spectrometry. There were 18 statistically significant differences in concentrations of metabolites and 3 differences in their ratios between HFpEF and hypertension groups. The prognostic model for detecting the possibility of HFpEF included seven metabolites and two ratios: hexadecenoylcarnitine, arginine, trimethylamine-N-oxide, asymmetric dimethylarginine (ADMA), arginine\/ADMA ratio, kynurenine, kynurenine\/tryptophan, neopterin, and anthranilic acid. The area under the ROC curve was 0.981 \u00b1 0.017. The resulting model was statistically significant (p &lt; 0.001). The metabolomic panel could be considered as an addition to the present HFpEF laboratory diagnostic criteria for blood plasma analysis in clinical practice.<\/jats:p>","DOI":"10.3390\/ijms26052102","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T05:13:58Z","timestamp":1740633238000},"page":"2102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolomic Panel for the Diagnosis of Heart Failure with Preserved Ejection Fraction"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4778-7755","authenticated-orcid":false,"given":"Maria V.","family":"Kozhevnikova","sequence":"first","affiliation":[{"name":"Hospital Therapy No. 1 Department, N.V. Sklifosovskiy Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-7713","authenticated-orcid":false,"given":"Anastasiia V.","family":"Kakotkina","sequence":"additional","affiliation":[{"name":"Hospital Therapy No. 1 Department, N.V. Sklifosovskiy Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-704X","authenticated-orcid":false,"given":"Ekaterina O.","family":"Korobkova","sequence":"additional","affiliation":[{"name":"Hospital Therapy No. 1 Department, N.V. Sklifosovskiy Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9785-5949","authenticated-orcid":false,"given":"Ivan V.","family":"Kuznetsov","sequence":"additional","affiliation":[{"name":"Hospital Therapy No. 1 Department, N.V. Sklifosovskiy Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-3936","authenticated-orcid":false,"given":"Ksenia M.","family":"Shestakova","sequence":"additional","affiliation":[{"name":"Centre of Biopharmaceutical Analysis and Metabolomics, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University (Sechenov University), 117418 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-8913","authenticated-orcid":false,"given":"Natalia E.","family":"Moskaleva","sequence":"additional","affiliation":[{"name":"Centre of Biopharmaceutical Analysis and Metabolomics, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University (Sechenov University), 117418 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9032-1558","authenticated-orcid":false,"given":"Svetlana A.","family":"Appolonova","sequence":"additional","affiliation":[{"name":"Centre of Biopharmaceutical Analysis and Metabolomics, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University (Sechenov University), 117418 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3014-6129","authenticated-orcid":false,"given":"Yuri N.","family":"Belenkov","sequence":"additional","affiliation":[{"name":"Hospital Therapy No. 1 Department, N.V. Sklifosovskiy Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University (Sechenov University), 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global Burden of Heart Failure: A Comprehensive and Updated Review of Epidemiology","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.18087\/cardio.2021.4.n1628","article-title":"Chronic Heart Failure in the Russian Federation: What Has Changed over 20 Years of Follow-Up? Results of the EPOCH-CHF Study","volume":"61","author":"Polyakov","year":"2021","journal-title":"Kardiologiya"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics an Updated 2024 Report from the Heart Failure Society of America","volume":"31","author":"Bozkurt","year":"2024","journal-title":"J. Card. Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial Stiffness in Patients with Heart Failure and a Preserved Ejection Fraction","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2016.05.019","article-title":"The HFpEF Obesity Phenotype","volume":"68","author":"Kitzman","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA\u2013PEFF Diagnostic Algorithm: A Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_9","first-page":"8","article-title":"Russian Scientific Medical Society of Internal Medicine Guidelines for Heart Failure: Chronic (CHF) and Acute Decompensated (ADHF). Diagnosis, Prevention and Treatment","volume":"58","author":"Mareev","year":"2018","journal-title":"Kardiologiia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.5603\/KP.2016.0141","article-title":"2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"74","author":"Ponikowski","year":"2016","journal-title":"Kardiol. Pol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18087\/cardio.2018.9.10172","article-title":"Metabolomic Profiling of Patients with Cardiovascular Diseases","volume":"17","author":"Belenkov","year":"2018","journal-title":"Kardiologiia"},{"key":"ref_12","first-page":"224","article-title":"Soluble ST2 and Galectin-3: What We Know and Don\u2019t Know Analytically","volume":"27","author":"Mueller","year":"2016","journal-title":"EJIFCC"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/eurjhf\/hft077","article-title":"Galectin-3 in Heart Failure with Preserved Ejection Fraction","volume":"15","author":"Edelmann","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijcard.2020.01.039","article-title":"Prognostic Value of SST2 in Patients with Heart Failure with Reduced, Mid-Range and Preserved Ejection Fraction","volume":"304","author":"Song","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wang, Z., Pan, X., Xu, H., Wu, Y., Jia, X., Fang, Y., Lu, Y., Xu, Y., Zhang, J., and Su, Y. (2022). Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients with Acute Heart Failure. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.812654"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jjcc.2018.10.012","article-title":"Soluble ST2 and Brain Natriuretic Peptide Predict Different Mode of Death in Patients with Heart Failure and Preserved Ejection Fraction","volume":"73","author":"Sugano","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1002\/ehf2.12923","article-title":"Metabolomic Signatures of Cardiac Remodelling and Heart Failure Risk in the Community","volume":"7","author":"Andersson","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cca.2020.04.035","article-title":"Relationship between the Plasma Acylcarnitine Profile and Cardiometabolic Risk Factors in Adults Diagnosed with Cardiovascular Diseases","volume":"507","author":"Kukharenko","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/MCB.01085-10","article-title":"Mouse Cardiac Acyl Coenzyme a Synthetase 1 Deficiency Impairs Fatty Acid Oxidation and Induces Cardiac Hypertrophy","volume":"31","author":"Ellis","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCRESAHA.112.268128","article-title":"Cardiac-Specific Deletion of Acetyl CoA Carboxylase 2 Prevents Metabolic Remodeling during Pressure-Overload Hypertrophy","volume":"111","author":"Kolwicz","year":"2012","journal-title":"Circ. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1002\/ehf2.14116","article-title":"Nitric Oxide Metabolites: Associations with Cardiovascular Biomarkers and Clinical Parameters in Patients with HFpEF","volume":"9","author":"Piatek","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.trsl.2020.08.007","article-title":"TMAO: How Gut Microbiota Contributes to Heart Failure","volume":"228","author":"Zhang","year":"2021","journal-title":"Transl. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41374-018-0091-y","article-title":"Gut Microbe-Derived Metabolite Trimethylamine N-Oxide Induces Cardiac Hypertrophy and Fibrosis","volume":"99","author":"Li","year":"2018","journal-title":"Lab. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1016\/j.jacc.2017.10.064","article-title":"Trimethylamine-N-Oxide and Heart Failure with Reduced versus Preserved Ejection Fraction","volume":"70","author":"Schuett","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1177\/2047487319870355","article-title":"Combined Use of Trimethylamine N-Oxide with BNP for Risk Stratification in Heart Failure with Preserved Ejection Fraction: Findings from the DIAMONDHFpEF Study","volume":"27","author":"Salzano","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.19163\/2307-9266-2022-10-2-130-153","article-title":"Activity Modulation of Various Nitric Oxide Syntases as an Approach to Endothelial Dysfunction Therapy","volume":"10","author":"Kurkin","year":"2022","journal-title":"Pharm. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Fazio, F., Carrizzo, A., Lionetto, L., Damato, A.L., Capocci, L., Ambrosio, M., Battaglia, G., Bruno, V., Madonna, M., and Simmaco, M. (2017). Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00214"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41380-019-0414-4","article-title":"The Kynurenine Pathway: A Finger in Every Pie","volume":"25","author":"Savitz","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref_29","first-page":"722","article-title":"[Similarities and Differences of Myocardial Metabolic Characteristics between HFpEF and HFrEF Mice Based on LC-MS\/MS Metabolomics]","volume":"51","author":"Zhang","year":"2023","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ejhf.1076","article-title":"Nuclear Magnetic Resonance-Based Metabolomics Identifies Phenylalanine as a Novel Predictor of Incident Heart Failure Hospitalisation: Results from PROSPER and FINRISK 1997","volume":"20","author":"Delles","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Marcinkiewicz-Siemion, M., Kaminski, M., Ciborowski, M., Ptaszynska-Kopczynska, K., Szpakowicz, A., Lisowska, A., Jasiewicz, M., Tarasiuk, E., Kretowski, A., and Sobkowicz, B. (2020). Machine-Learning Facilitates Selection of a Novel Diagnostic Panel of Metabolites for the Detection of Heart Failure. Sci. Rep., 10.","DOI":"10.1038\/s41598-019-56889-8"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3784589","DOI":"10.1155\/2018\/3784589","article-title":"Amino Acid-Based Metabolic Panel Provides Robust Prognostic Value Additive to B-Natriuretic Peptide and Traditional Risk Factors in Heart Failure","volume":"2018","author":"Wang","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jacc.2015.02.018","article-title":"Metabolic Disturbances Identified in Plasma Are Associated with Outcomes in Patients with Heart Failure","volume":"65","author":"Cheng","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102968","DOI":"10.1161\/JAHA.115.003190","article-title":"Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure with Preserved versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure","volume":"5","author":"Hunter","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1373\/clinchem.2016.257279","article-title":"A Novel Lipid Biomarker Panel for the Detection of Heart Failure with Reduced Ejection Fraction","volume":"63","author":"Lutz","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.15829\/1560-4071-2020-3-3786","article-title":"Arterial Hypertension in Adults. Clinical guidelines 2020","volume":"25","author":"Kobalava","year":"2020","journal-title":"Russ. J. Cardiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:43:24Z","timestamp":1760028204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26052102"],"URL":"https:\/\/doi.org\/10.3390\/ijms26052102","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}